新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
Abstract
Provided herein are novel phenylpiperidine derivatives as QPCT and QPCTL inhibitors, pharmaceutical compositions, use of such compounds in treating cancer or fibrotic diseases, and processes for preparing such compounds.
摘要
本文提供了作为QPCT和QPCTL抑制剂的新型苯基哌啶衍生物、药物组合物、此类化合物在治疗癌症或纤维化疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
2
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2025 Apr 2;16(4):540-541. doi: 10.1021/acsmedchemlett.5c00142. eCollection 2025 Apr 10.
3
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2025 Apr 14;16(5):758-759. doi: 10.1021/acsmedchemlett.5c00198. eCollection 2025 May 8.
4
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
5
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
6
Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Oct 14;15(11):1806-1807. doi: 10.1021/acsmedchemlett.4c00485. eCollection 2024 Nov 14.
7
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Aug 21;15(9):1435-1436. doi: 10.1021/acsmedchemlett.4c00408. eCollection 2024 Sep 12.
8
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
9
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
10
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
引用本文的文献
1
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2025 Apr 2;16(4):540-541. doi: 10.1021/acsmedchemlett.5c00142. eCollection 2025 Apr 10.
本文引用的文献
1
How chemokines organize the tumour microenvironment.
Nat Rev Cancer. 2024 Jan;24(1):28-50. doi: 10.1038/s41568-023-00635-w. Epub 2023 Dec 8.
2
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.
Drug Discov Today. 2023 Oct;28(10):103644. doi: 10.1016/j.drudis.2023.103644. Epub 2023 May 26.
3
Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
Eur J Pharmacol. 2022 Sep 15;931:175178. doi: 10.1016/j.ejphar.2022.175178. Epub 2022 Aug 7.
4
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
J Cancer Res Clin Oncol. 2022 Jan;148(1):1-14. doi: 10.1007/s00432-021-03815-z. Epub 2021 Oct 5.
Zotero 插件